Misplaced Pages

Alinidine

Clinical data
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine
CAS Number	33178-86-8
PubChem CID	36354
ChemSpider	33429
UNII	E7IDJ8DS1D
ChEMBL	ChEMBL278581
CompTox Dashboard (EPA)	DTXSID4022571
ECHA InfoCard	100.164.275
Chemical and physical data
Formula	C12H13Cl2N3
Molar mass	270.16 g·mol
3D model (JSmol)	Interactive image
SMILES Clc2cccc(Cl)c2N(/C1=N/CCN1)C\C=C
InChI InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16) Key:OXTYVEUAQHPPMV-UHFFFAOYSA-N
(what is this?)  (verify)

Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold. The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.

Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.

References

1. Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflügers Arch 1987, 410:83-91
2. Current Opinion in Pharmacology 2007, 7:208–213
3. Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy". J Am Coll Cardiol. 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.

• Drugs not assigned an ATC code
• Antiarrhythmic agents
• Chloroarenes
• Anilines
• Imidazolines
• Allylamines